<DOC>
	<DOC>NCT01298505</DOC>
	<brief_summary>The purpose of this study in healthy people is to investigate the safety, toleration and time course of PF-03654764 in the blood, following multiple doses given by mouth together with fexofenadine.</brief_summary>
	<brief_title>A Study To Investigate The Safety And Toleration Of Multiple Oral Doses Of PF-03654764 In Combination With Fexofenadine In Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Fexofenadine</mesh_term>
	<mesh_term>Terfenadine</mesh_term>
	<criteria>Healthy subjects. (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12lead ECG and clinical laboratory tests). Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). A positive urine drug screen. Treatment with an investigational drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 halflives preceding the first dose of study medication.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Phase 1 multiple dose safety toleration fexofenadine</keyword>
</DOC>